Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? – a pharmacoeconomic study. (2024). Headache Medicine, 15(Supplement), 98. https://headachemedicine.com.br/hm/article/view/1230